Development of the first thermolytic to suppress shivering and seizure
Ended Project Grant Awarded Last action
- Award ID
- R41HL135964
- Recipient
-
Be Cool Pharmaceutics LLC UEI TG8PD8YBNQG3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $457,306
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Alaska, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $55,000 | |
| Amendment | $103,435 | |
| Original award | $298,871 |
Quick answers
Who received award R41HL135964?
R41HL135964 was awarded to Be Cool Pharmaceutics LLC by National Heart Lung and Blood Institute (National Institutes of Health) on September 1, 2017.
How much is award R41HL135964 worth?
$457,306 has been obligated on R41HL135964.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award